Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the tumor site, enabling them to target cancer cells in solid tumors.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Camurus, Clene, Hemispherian, Jazz, Mesoblast, Vertex.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abeona, Alvotech, Advanz, Bergenbio, Beacon, Bioeq, Biomarin, Bio Usawa, Concentra, Ho’ola, IGM, Inozyme, Merck, Oncoinvent, Oncternal, Protagonist, Torii, Verrica.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alligator, Arcturus, Atai, Beckley, Cytodyn, I-Mab, Mineralys, Sensorion, Verastem.
It may be a year later than originally planned, but Regeneron Pharmaceuticals Inc. is set to commercialize Lynozyfic (linvoseltamab) in the U.S. following FDA approval for use in adults with relapsed and refractory multiple myeloma. A bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, Lynozyfic was cleared under the accelerated approval pathway, with continued approval contingent upon a confirmatory trial.
Puretech Health plc’s rollout May 20 of more phase IIb data with deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis (IPF) perked optimism for that compound – a deuterated form of p38 MAP kinase inhibitor pirfenidone – as well as others in the busy therapeutic space.
The BioWorld Cancer Index reversed its early year losses, rebounding from a 4.74% decline at the end of the first quarter (Q1) to finish Q2 up 12.78%. The Dow Jones Industrial Average followed a similar pattern, dropping to -4.41% by the end of April before recovering to a 3.64% gain by Q2’s end. Meanwhile, the Nasdaq Biotechnology Index, down 5.37% at the end of May, narrowed its losses to close June down just 1.92%.
RSS
